|
A six-month, phase 3, multicenter, masked, randomized, sham-controlled trial (with six-month open-label extension) to assess the safety and efficacy of 700 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion. ( 7/2006 - 12/2007 )
|